Mounjaro and Wegovy Compared: How GLP-1 Diet Injections Suppress Appetite and What Happens When You Stop

Two names have completely taken over weight-loss conversations in the clinic: Mounjaro and Wegovy. Not long ago, obesity was still largely framed as a willpower problem. That perception has shifted fast — and for good reason. These injectable medications work directly on the hormones that drive appetite, and the weight-loss results in clinical trials surpass anything we saw from previous medications. The attention is well-founded. But most patients who come in have heard about results from a friend or seen before-and-afters online, and they don't yet have a clear picture of what these drugs actually do inside the body, how the two differ, or what happens when you stop. With medications this powerful, that understanding matters. What follows is what I walk every patient through before we decide whether to start.

What kind of drugs are these, exactly?

The chart above shows average body weight reduction across three GLP-1 class medications. Liraglutide comes in at roughly 8%, semaglutide at approximately 14.9%, and tirzepatide at around 20.9%. The pattern is clear: the more hormonal pathways engaged, the more weight lost. One important caveat — these figures come from separate trials with different designs, so they are not a head-to-head comparison.

Both Wegovy and Mounjaro mimic a hormone called GLP-1, which your gut naturally releases after eating. GLP-1 belongs to a group called incretins. It prompts the pancreas to release insulin, lowering post-meal blood sugar, while also sending satiety signals to the brain's appetite centers, your body's built-in "I've had enough" switch. Wegovy's active ingredient, semaglutide, does what GLP-1 does, but with one important change: your body's own GLP-1 breaks down within minutes, while semaglutide is engineered to stay active for about a week. It started out as a diabetes medication, which you may know as Ozempic, before strong weight-loss data earned it a separate FDA approval as Wegovy for chronic weight management.

Mounjaro goes a step further. Its active ingredient, tirzepatide, targets not only GLP-1 but also a second incretin hormone called GIP. That dual mechanism is why it's called a dual agonist: instead of pressing one satiety switch, it presses two at once. The exact independent role of GIP is still being worked out, but stimulating both receptors together produces a stronger effect on appetite and metabolic regulation. One thing US patients should know: tirzepatide is sold under two brand names, Mounjaro for type 2 diabetes and Zepbound for obesity. Same molecule, two FDA indications.

One thing to be clear about from the start: neither drug directly burns fat or melts it away. They change how much you want to eat and how quickly you feel full. The target is the brain and the gut, not the fat cells themselves. Patients who assume the medication handles everything and pay no attention to diet tend to see weaker results, and they regain weight faster after stopping. The differences in the bar chart come down to how powerfully each drug shifts appetite.

How does the weight actually come off?

The main driver is appetite suppression, but not the white-knuckling-through-hunger kind. These medications act on the hypothalamus and connected appetite circuits to reduce how hungry you actually feel, while boosting satiety so you feel full on smaller amounts. Patients who previously would have finished a full plate often find themselves naturally setting down the fork halfway through. It isn't willpower. The desire to keep eating simply decreases. That makes these medications meaningfully different from dieting, where you're constantly fighting a biological pull toward more food.

Layered on top of that is delayed gastric emptying. The medications slow how quickly food moves from your stomach into the small intestine. Food lingers longer, which extends fullness and cuts the urge to snack between meals. The stomach empties over three or four hours instead of one. This is also what causes the nausea many patients get early on, which I'll come to shortly. Eating smaller portions and cutting back on high-fat meals makes it significantly more manageable.

A question I hear constantly: can you lose weight on this without exercising? The medication does meaningfully reduce caloric intake. But when weight comes off, it isn't pure fat loss — lean muscle mass decreases too, especially when weight comes off quickly. Without resistance training and sufficient protein intake, the weight lost is of lower quality, and the rebound after stopping is sharper. Exercise isn't optional; it largely determines whether these results hold over time.

The first thing most patients notice isn't the number on the scale. It's a changed relationship with food. "I just don't think about eating as much" and "I stop halfway through and I'm done" are the phrases I hear most. Weight loss follows from that shift. And when the medication stops, appetite returns to baseline and the weight follows. The chart above captures this. Patients who continued treatment lost an additional 7.9% of body weight on average; those who stopped regained an average of 6.9%. The two bars go in opposite directions: once appetite suppression lifts, much of what was lost comes back. This is the main reason these medications are a long-term commitment rather than a short course, which I'll return to at the end.

What do the clinical trials actually show?

The chart above breaks down the numbers. Semaglutide 2.4mg produced approximately 14.9% average body weight reduction. Tirzepatide came in at roughly 15% at the 5mg dose, 19.5% at 10mg, and 20.9% at the highest 15mg dose. The stepwise increase with dose escalation is evident throughout — more drug, more effect.

The landmark evidence behind Wegovy is the STEP 1 trial. Adults with obesity received semaglutide 2.4mg once weekly for 68 weeks. Average body weight fell by approximately 14.9%, meaning someone starting at 250 lbs lost roughly 37 lbs on average. The diet-and-exercise-only control group lost about 2.4%. That gap is large and clinically meaningful.

One qualifier that matters: 14.9% is an average. Individual responses vary considerably. Some patients exceed that number substantially; others see more modest results on the identical dose. That's why I ask patients to treat the first few months as an observation period to understand how their own body responds — not as a guarantee of a specific outcome.

The key trial for Mounjaro is SURMOUNT-1. Tirzepatide was administered once weekly for 72 weeks, and results varied by dose: approximately 15% at 5mg, 19.5% at 10mg, and 20.9% at the maximum 15mg dose.

The critical point about comparing these two drugs: both sets of results come from separate studies with different participants, durations, and management protocols. Placing the numbers side by side is not the same as a head-to-head trial. You cannot conclude from these figures that Mounjaro is precisely X percent more effective than Wegovy. The accurate read is that both produce substantial weight loss, with tirzepatide's higher doses reporting the largest reductions observed in this drug class to date.

How do Mounjaro and Wegovy actually differ?

The most fundamental difference is how many hormonal pathways each drug engages. Wegovy targets GLP-1 alone. Mounjaro and Zepbound (tirzepatide) target both GLP-1 and GIP simultaneously. The larger weight-loss numbers seen with tirzepatide in the trials are thought to reflect this dual mechanism. That extra potency can also mean more GI side effects, especially at higher doses and during titration.

Both medications are once-weekly subcutaneous self-injections delivered via a pre-filled pen into the abdomen or thigh. Weekly rather than daily dosing is a real practical advantage over older options like Saxenda (liraglutide), which requires an injection every day. Both drugs also start low and step up gradually, roughly every four weeks, rather than beginning at the full therapeutic dose. That titration schedule exists specifically to reduce GI side effects. Patients who push ahead of the schedule get worse nausea and are more likely to quit the medication entirely. Slower titration gets you further.

A naming note that trips up a lot of patients: brand names and active ingredients are different things. Mounjaro = tirzepatide (FDA-approved for type 2 diabetes). Zepbound = tirzepatide (FDA-approved for obesity). Same molecule, two separate FDA indications and two brand names. Wegovy = semaglutide 2.4mg (for obesity). Ozempic = semaglutide 0.5–2mg (for type 2 diabetes). Again, same molecule, different approved doses and indications. Saxenda is a completely different drug — liraglutide, an older GLP-1 agonist requiring daily injections and producing a smaller average weight-loss effect. These names look and sound similar enough that confusion is common, even among patients who've been on one of them for months.

Side effects and what you need to know before starting

GI symptoms dominate the side-effect profile, and the chart above shows the scale. In a pooled analysis of the STEP 1–3 trials for semaglutide 2.4mg, nausea occurred in 43.9% of participants, diarrhea in 29.7%, and vomiting in 24.5%. Nearly half of patients had nausea. If you're starting either of these medications, nausea is the side effect you're most likely to run into first. These symptoms come directly from the delayed gastric emptying that also drives the weight loss, so in that sense they're often a sign the drug is doing its job. They usually peak early, either when starting or when stepping up the dose, and ease off as the body adapts. Eating smaller meals and reducing dietary fat makes a noticeable difference.

There are contraindications that are absolute. Both Wegovy and Mounjaro carry an FDA boxed warning covering a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Thyroid tumor risk was identified in animal studies, and this is a hard contraindication for both drugs. Separately, patients with a history of pancreatitis, gallbladder disease, or those who are pregnant or planning to become pregnant need a careful individualized discussion before starting. These are not automatic disqualifiers, but they require clinical judgment and close monitoring.

The practical implication: I'd caution against getting these medications through compounding pharmacies, online sources, or any channel outside of a real prescriber-patient relationship. Beyond the safety and regulatory concerns around compounded GLP-1 products, the clinical problems are real. Dosing, titration, monitoring for adverse effects, and screening for contraindications all require ongoing medical context that a prescription without a relationship doesn't provide.

The point patients most often underestimate, and the one I spend the most time on, is the weight regain after stopping. When the medication stops, appetite returns toward baseline, caloric intake climbs back, and a good portion of the lost weight tends to come back. The STEP 4 data in the earlier chart make this concrete. These medications treat obesity as a chronic condition, not something you fix with a course of injections and move on from. The lifestyle work done during treatment, building a protein-rich diet and a consistent resistance-training habit, is what holds once the drug is no longer doing the heavy lifting.

What's the current access situation in the US?

Both Wegovy and Zepbound are FDA-approved and commercially available in the United States. Ozempic and Mounjaro, the diabetes-indication versions of the same active ingredients, are also widely prescribed, and have at times been used off-label for weight management when the obesity-labeled versions were unavailable. Saxenda remains on the market but has been largely displaced in clinical practice by the more effective once-weekly options.

Supply has been a persistent issue. When the weight-loss results became widely known, global demand surged well beyond what manufacturers anticipated, and both semaglutide and tirzepatide have gone through shortage periods. Availability varies by pharmacy and has fluctuated considerably — checking current stock with your specific pharmacy directly remains the most accurate method.

Cost and insurance coverage are real barriers for many patients. Without insurance, monthly costs can run several hundred dollars, and because maintaining results often requires ongoing treatment, the cumulative expense adds up quickly. Coverage varies significantly by plan and has been in flux. Medicare Part D expanded coverage of Wegovy following the SELECT cardiovascular outcomes trial, but coverage for obesity management alone, separate from cardiovascular indications, remains inconsistent across private payers. Prior authorization requirements are common. Have your provider's office verify your specific benefit before assuming access.

One more thing worth stating plainly: these are powerful medications with a genuine clinical track record, but they're not appropriate for everyone. Your BMI, coexisting medical conditions, contraindication history, and realistic capacity for long-term treatment are all part of the decision. Using either drug primarily for cosmetic slimming when you don't meet clinical weight thresholds shifts the risk-benefit balance in a way that doesn't favor the patient. If you're considering Wegovy or Mounjaro, the right starting point is a conversation with a provider who can review your full medical history, not sourcing the medication first and asking questions later.